Actinver Research - Genomma Lab 4Q24: Model Update Post 2Q25
We reiterate our Outperform rating, while slightly lowering our PT to P$29 (from P$30) post quiet period, as we continue to see meaningful...
166 Views
Actinver Research - Genomma Lab 4Q24: Strong finish and positive outlook
Revenues of P$4.7bn grew 32.4% YoY, supported by healthy growth across all regions and FX tailwinds (e.g., U.S. sales grew 1.8% in local currency,...
217 Views
Actinver Research - Genomma Lab 4Q24: Healthy finish of the year (Quick View)
Revenues of P$4.7bn grew 32.4% YoY, supported by healthy growth across all regions. Sales in Mexico were in line with our estimates, while in...
253 Views
Actinver Research - Genomma Lab: Reaching Healthier Valuation Levels (Company Update)
After a stunning YTD performance (up 90.68% as of 12/9/24 vs MEXBOL 9.05% down), we continue to see solid upside ahead. Market conditions for most...
283 Views
Actinver Research - Genomma Lab 3Q24: Strong across the board (Quick View)
Revenues of P$5.1bn grew 15.9% YoY and were 6.8% above our estimates, supported by healthy growth across all regions. For a second consecutive...
203 Views